MAL expression in lymphoid cells: Further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas

Institute of Pathology, Universität Ulm, Ulm, Baden-Württemberg, Germany
Modern Pathology (Impact Factor: 6.36). 12/2002; 15(11):1172-80. DOI: 10.1097/01.MP.0000032534.81894.B3
Source: PubMed

ABSTRACT The MAL mRNA was initially identified during T-cell development and was later found in myelin-forming cells and certain polarized epithelial cell lines. It encodes a proteolipid believed to participate in membrane microdomains stabilization, transport machinery and signal transduction. Using a differential display reverse-transcription approach, we identified MAL as a distinct molecular marker of primary mediastinal large B-cell lymphoma compared with nonmediastinal diffuse large B-cell lymphomas. In the present study, we used immunohistochemistry to extend MAL expression analysis to normal lymphoid tissues; to 185 lymphomas representing most B, T, and Hodgkin lymphoma entities; and to the primary mediastinal large B-cell lymphoma derived B-cell line MedB-1. In addition, B and T cells from peripheral blood, tonsil, and spleen were analyzed by flow cytometry. Our results show that MAL is highly expressed in thymocytes, in a large percentage of peripheral CD4 T cells, and in a lower proportion of CD8 peripheral T cells. In the normal B-cell compartment, MAL expression appears to be restricted to a minor subpopulation of thymic medullary B cells and to occasional mature plasma cells located in the interfollicular areas of tonsil and lymph nodes. Among B-cell lymphomas (n = 110), MAL expression in tumor cells was observed in 21/33 primary mediastinal large B-cell lymphomas (70%) and in 3/5 plasmacytoma/myeloma, but not in all other B-cell lymphomas with the exception of 1/33 nonmediastinal diffuse large B-cell lymphomas. The MedB-1 B-cell line was also MAL positive. Among T-cell neoplasms, MAL was highly expressed in lymphoblastic tumors (5/6), whereas mature T-cell lymphomas were essentially MAL negative (27/28). Among 41 Hodgkin lymphomas, 3 nodular-sclerosing cases with mediastinal involvement showed MAL-positive Reed Sternberg cells. In conclusion, this study further supports thymic B cells as the putative normal counterpart of primary mediastinal large B-cell lymphomas and supports MAL as a distinct molecular marker of this lymphoma subtype among diffuse large B-cell lymphomas.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Résumé: Les biopuces à ADN font partie des avancées technologiques importantes des toutes dernières années qui permettent d’ouvrir la voie à une compréhension plus globale et plus approfondie de la biologie tumorale. Par l’hybridation de l’ADN complémentaire synthétisé à partir d’un échantillon tumoral sur une surface contenant des séquences de gènes différents, cette technique va permettre en une seule étape d’évaluerde façon quantitative l’expression de plusieurs milliers de gènes au sein de cette tumeur. Les lymphomes malins, de par leur hétérogénéité tant biologique que clinique, constituent un modèle de choix pour l’utilisation de ce nouvel outil. Appuyée sur des analyses bioinformatiques complexes, l’analyse de plusieurs séries d’échantillons a récemment permis la description des voies de signalisation activées dans ces tumeurs lymphoïdes, aboutissant à la reconnaissance de la proximité ou au contraire à l’individualisation de certains sous-types histologiques, à l’identification de prédicteurs biologiques de diagnostic ou de pronostic, et enfin à la caractérisation de nouvelles cibles pour des agents pharmacologiques spécifiques. À travers les publications réalisées à ce jour, nous allons discuter dans cette revue l’impact de cette technique sur la compréhension de la biologie et la clinique des lymphomes malins, de type Hodgkinien et non Hodgkinien.
    Oncologie 05/2006; 8(4):314-321. DOI:10.1007/s10269-006-0389-z · 0.08 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Primary mediastinal B-cell lymphoma (PMBCL) is a relatively rare lymphoma subtype affecting mainly young adults. Its molecular signature and clinical features resemble classical Hodgkin lymphoma. The optimal chemotherapy for this lymphoma subtype has not been established. The addition of rituximab to anthracycline based chemotherapy improved response rates and survival. Many centers use R-CHOP as standard treatment, but the role of the intensified regimens and consolidation radiotherapy has to be clarified. Recent data coming from retrospective analyses and an ongoing prospective study addressing the problem of consolidation radiotherapy will help to better identify risk groups and apply risk-adapted and effective treatment strategies. The latest research has helped to understand molecular mechanisms of PMBCL pathogenesis and indicated targets of directed therapy for the future.
    Current Hematologic Malignancy Reports 06/2014; 9(3). DOI:10.1007/s11899-014-0219-0 · 2.29 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Primary mediastinal B-cell lymphoma (PMBL) is a highly aggressive disease with a unique set of biological, clinical, morphological, immunological and in particular genetic features that in the molecular era of defining lymphomas clearly distinguishes it as a separate entity from other diffuse large B-cell lymphomas (DLBCL). A precise molecular diagnosis of PMBL can be achieved by gene expression profiling. The signature gene expression profile of PMBL is more closely related to classic Hodgkin lymphoma (cHL) than to other DLBCL subgroups. A number of common genetic aberrations in PMBL and cHL further underscore their close relationship. To investigate the pathobiology of lymphomas in depth, many groups have turned to cell lines that are suitable models facilitating molecular studies and providing unique insights. For the purposes of the current perspective, we focus on four bona fide PMBL-derived cell lines (FARAGE, KARPAS-1106, MEDB-1, U-2940) that we identified and validated as such through hierarchical cluster analysis among a large collection of leukemia-lymphoma cell lines. These gene expression profiles showed that the four PMBL cell lines represent a distinct entity and are most similar to cHL cell lines, confirming derivation from a related cell type. A validated cell line resource for PMBL should assist those seeking druggable targets in this entity. This review aims to provide a comprehensive overview of the currently available cellular models for the study of PMBL. Copyright © 2014 Elsevier Ltd. All rights reserved.
    Leukemia Research 11/2014; 39(1). DOI:10.1016/j.leukres.2014.11.002 · 2.69 Impact Factor


Available from